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ABSTRACT
BACKGROUND: Prognostic markers of bone metastatic clear cell renal cell cancer 
(ccRCC) are poorly established. We tested prognostic value of HIF1a/HIF2a and their 
selected target genes in primary tumors and corresponding bone metastases.
RESULTS: Expression of HIF2a was lower in mRCC both at mRNA and protein 
levels (p/mRNA/=0.011, p/protein/=0.001) while HIF1a was similar to nmRCC. At 
the protein level, CAIX, GAPDH and GLUT1 were increased in mRCC. In all primary 
RCCs, low HIF2a and high HIF1a as well as CAIX, GAPDH and GLUT1 expressions 
correlated with adverse prognosis, while VEGFR2 and EPOR gene expressions were 
associated with favorable prognosis. Multivariate analysis confirmed high HIF2α 
protein expression as an independent risk factor. Prognostic validation of HIFs, 
LDH, EPOR and VEGFR2 in RNA-Seq data confirmed higher HIF1a gene expression in 
primary RCC as an adverse (p=0.07), whereas higher HIF2a and VEGFR2 expressions 
as favorable prognostic factors. HIF1a/HIF2a-index (HIF-index) proved to be an 
independent prognostic factor in both the discovery and the TCGA cohort.
PATIENTS AND METHODS: Expressions of HIF1a and HIF2a as well as their 7 
target genes were analysed on the mRNA and protein level in 59 non-metastatic 
ccRCCs (nmRCC), 40 bone metastatic primary ccRCCs (mRCC) and 55 corresponding 
bone metastases. Results were validated in 399 ccRCCs from the TCGA project.
CONCLUSIONS: We identified HIF2a protein as an independent marker of the 
metastatic potential of ccRCC, however, unlike HIF1a, increased HIF2a expression is 
a favorable prognostic factor. The HIF-index incorporated these two markers into a 
strong prognostic biomarker of ccRCC.
               Research Paper
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INTRODUCTION
Among kidney cancers, clear cell renal cancer 
(ccRCC) is the histologically predominant form, which is 
a genetically heterogeneous malignancy [1]. A prominent 
pathological feature of ccRCC is its rich vasculature [2] 
due to the dysfunction of von Hippel-Lindau gene (VHL) 
and deregulation of hypoxia inducible factors (HIF) 
resulting in specific gene expression changes, which 
promote neoangiogenesis through vascular endothelial 
growth factor (VEGFs) and vascular endothelial growth 
factor receptor (VEGFRs) expressions [3]. Activity 
of HIFs further results in metabolic switch (affecting 
expression and function of glucose transporter 1 
(GLUT1), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), carbonic anhydrase 9 (CAIX), erythropoietin 
receptor (EPOR) and lactate-dehydrogenase 5 (LDH5), 
providing a selection benefit for the tumor cells.
ccRCC is characterized by specific metastatic 
patterns, being lungs, liver and skeletal system the 
most frequently affected sites. Since metastatization 
is an organ selective process, it might rely on different 
geno- or phenotypes in various organs [4, 5]. In ccRCC, 
development of bone metastasis is considered a adverse 
prognostic factor [6]. A preliminary study raised the 
possibility that HIF1α and its target genes could be 
involved in shaping bone metastatic potential of ccRCC 
[7].
Although, the Fuhrman grading is still one of the 
best prognostic factors in ccRCC [8], this is also true 
in case of bone metastatic diseases [6]. Combined tools 
have been developed to predict therapy response, initially 
the Memorial Sloan-Kettering Cancer Center (MSKCC) 
nomogram stratified ccRCC into risk categories responsive 
to interferon therapy [9]. However, especially in the era of 
targeted treatment, the search for biomarkers continues, 
with several candidates emerging from the VHL-HIF 
pathway [10].
The simplistic VHL-HIF pathway driven angiogenic 
phenotype of ccRCC underwent a considerable 
redefinition recently. It was discovered by deep sequencing 
analysis that ccRCC can be further subclassified on 
the basis of mutations either of several transcriptional 
regulators, such as PBRM1 (polybromo-1), ARID1A (AT-
rich interactive domain-containing protein 1A), BAP1 
(BRCA1 associated protein-1), JARID2C (lysine-specific 
demethylase 5C), SETD2 (SET domain containing 2), or 
of the PTEN (phosphatase and tensin homolog)-mTOR 
(mammalian target of rapamycin) pathway members [11]. 
If transcriptional regulator mutations are also a hallmark 
of at least a large fraction of ccRCC we can postulate that 
the angiogenic phenotype of ccRCC may be defined at 
transcriptional levels as well, activating the expression of 
HIF family genes, which then control expression of the 
angiogenic genes. Since prognostic data are scanty on 
bone metastatic RCC, in our current study we analyzed 
mRNA- and protein expressions of HIF1α and HIF2α as 
well as their target genes in bone metastatic ccRCC to 
reveal their possible prognostic significance.
RESULTS
Clinicopathological characteristics
FFPE samples of fifty-five bone-metastatic (mRCC) 
and fifty-nine non-metastatic ccRCC (nmRCC) patients 
were investigated using their primary tumors and their 
respective bone metastases as a metastatic cohort (mRCC, 
Supplementary Table S1). The clinical data are presented 
on (Table 1).
Analysis of HIF1α, HIF2α and HIF-regulated 
gene expressions in primary ccRCCs
While expression of HIF1α did not differ between 
the non-metastatic and bone-metastatic primary RCCs (p/
mRNA/=0.252, p/protein/=0.385), HIF2α was found to be 
significantly lower both at mRNA and protein levels in 
the metastatic tumors (p/mRNA/=0.011, p/protein/=0.001) 
(Figures 1 and 2).
The mRNA expressions of CAIX, EPOR, GAPDH, 
GLUT1, LDH5 and VEGF did not differ significantly 
in the metastatic versus non-metastatic primary tumors 
(Figure 1). However, at protein levels CAIX (p=0.001), 
GAPDH (p=0.001) and GLUT1 (p=0.002) showed 
elevated expression in bone metastatic primary RCC. 
VEGFR2 data were controversial, showing decreased 
expression at gene expression level (p/mRNA/=0.001) 
in mRCC, which could not be confirmed by 
immunohistochemistry (p/protein/=0.294).
Correlation analysis of expression of HIFs and 
their regulated genes has been performed. At both mRNA 
(Pearson’s correlation) and protein level (Spearman’s rank 
correlation) statistical significance was reached for several 
markers in relation to HIF expression (Supplementary 
Figure 1). The investigated markers display a stronger 
correlation to HIF2α than to HIF1α (Table 2).
Survival analysis
A risk score was then generated for each marker 
based on model coefficients. Resultant predicted 
risk scores were not only dichotomized at median 
expression (Figure 3) but at the 25th and 75th percentile 
as well, and corresponding Kaplan-Meier survival curves 
were generated and compared by log-rank statistics 
(Supplementary Figure 2). Elevated HIF1α mRNA 
proved to be an adverse prognostic factor for both distant-
metastasis-free survival (DMFS) and overall survival (OS), 
which was confirmed at protein level as well for DMSF. 
Furthermore, HIF2α levels were inversely correlated 
with prognosis both at mRNA (DMFS) and protein levels 
(DMFS and OS), but surprisingly low expression was 
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correlated with adverse prognosis. The HIF-regulated 
genes displayed limited prognostic power split into groups 
at median expression level and 25th and 75th percentiles 
(Supplementary Figure 2). These genes were also tested 
when grouped into clusters based on a threshold at median 
expression level. Then, CAIX, GAPDH and GLUT1 were 
prognostic at protein level for DMFS (higher expression 
resulting in poorer prognosis). CAIX, EPOR, GLUT1, 
VEGFR2 and VEGF were prognostic at mRNA level for 
DMFS (Table 3). Interestingly, at mRNA level the higher 
expression of EPOR, GLUT1 and VEGFR2 predicted 
better survival (Table 3).
To further test the power of HIF2α mRNA and 
protein expressions as prognostic factor in bone metastatic 
ccRCC, multivariate analysis was performed taking into 
account the available independent clinicopathological 
variables (gender, Fuhrman grade). According to this 
analysis, decreased HIF2α protein expression level 
remained an independent negative prognostic factor and 
outperformed all other clinicopathological factors, even 
HIF1α in multiple models (Table 4).
We also tested the combined prognostic power of 
HIF1α/HIF2α protein expressions. Survival analysis 
indicated that RCC patients characterized by HIF1α-
high/HIF2α-low marker profile had the worst outcome 
while the opposite was found for patients belonging to 
the HIF1α-low/HIF2α-high group (Figure 4). The HIF1α-
high/HIF2α-low or the HIF1α-low/HIF2α-low groups 
were found to fall in between the two previous prognostic 
groups (Table 5).
Validation cohort
We tested the prognostic power of mRNA 
expression of HIF1α, HIF2α and VEGFR2 in the publicly 
available RNA-Seq data of ccRCC from the TCGA project 
involving 399 patients (Figure 5). In this cohort the 
distribution of available clinicopathological characteristics 
was similar to our cohort (p/gender/=1.000), however, 
in the TCGA cohort bone metastatic cases could not 
be filtered since the localization of metastases was not 
disclosed and therefore contained cases not limited 
to skeletal metastases. Survival analysis for HIF1α 
expression confirmed that higher expression (split at 
median) predicted poor survival (p=0.07, HR=1.41), while 
the opposite was found for HIF2α: increased expression 
Table 1: Clinicopathological characteristics of the patients with primary RCCs included in the study
Variables/Group  mRCC nmRCC
Age (years) Mean (range) 61.08 (34-79) 60.87 (39-87)
  n % n %
Gender
Male 33 82 34 57
Female 7 17 25 42
Stage
1 17 42 42 71
2 7 17 9 15
3 8 20 5 8
Unknown 8 20 3 5
Metastases
None 0 0 59 100
Solitary osseal 25 62 0 0
Multiplex osseal 3 7 0 0
Osseal plus extra-
osseal 9 22 0 0
Unknown beyond 
osseal 3 7 0 0
Fuhrman Grade
1 15 37 20 34
2 16 40 31 52
3 7 17 5 8
4 2 5 3 5
Overall survival 
(months)
Mean 41.69 min.: 96.00 month
Standard Deviation 46.62 NA
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Figure 1: Expressions of HIF1α and HIF2α and their regulated genes at messenger ribonucleic acid (mRNA) level in 
primary non-metastatic (nmRCC) and metastatic renal cancer (mRCC) and in bone metastases (bMET). Asterisk means 
significant difference (metastatic vs. non-metastatic group, metastases vs. primary RCC, respectively); see p-values in text.
Figure 2: Expressions of HIF1α and HIF2α and their regulated genes at protein level in primary non-metastatic 
(nmRCC) and metastatic renal cancer (mRCC) and in bone metastases (bMET). Asterisk means significant difference 
(metastatic vs. non-metastatic group, metastases vs. primary RCC, respectively); see p-values in text.
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Table 2: Correlation of HIFs and their regulated genes and transcripts at mRNA (A) and protein (B) expression levels
A mRNA CAIX EPOR GAPDH GLUT1 HIF1α HIF2α LDH VEGFR VEGF
CAIX PC 1 0.26 0.244 0.828** 0.233 0.480** 0.256 0.255 0.452**
 p  0.057 0.06 0 0.078 0 0.05 0.057 0.001
EPOR PC 0.26 1 0.986** 0.022 0.276* 0.595** 0.999** 0.227 0.251
 p 0.057  0 0.872 0.034 0 0 0.087 0.063
GAPDH PC 0.244 0.986** 1 0.154 0.415** -0.201 0.993** 0.279* 0.161
 p 0.06 0  0.243 0 0.124 0 0.026 0.203
GLUT1 PC 0.828** 0.022 0.154 1 0.135 0.431** 0.157 0.144 0.299*
 p 0 0.872 0.243  0.322 0.001 0.234 0.284 0.028
HIF1α PC 0.233 0.276* 0.415** 0.135 1 0.543** 0.313* 0.182 -0.021
 p 0.078 0.034 0 0.322  0 0.011 0.154 0.869
HIF2α PC 0.480** 0.595** -0.201 0.431** 0.543** 1 0.02 0.667** -0.006
 p 0 0 0.124 0.001 0  0.881 0 0.967
LDH PC 0.256 0.999** 0.993** 0.157 0.313* 0.02 1 0.238 0.169
 p 0.05 0 0 0.234 0.011 0.881  0.058 0.185
VEGFR PC 0.255 0.227 0.279* 0.144 0.182 0.667** 0.238 1 0.159
 p 0.057 0.087 0.026 0.284 0.154 0 0.058  0.221
VEGF PC 0.452** 0.251 0.161 0.299* -0.021 -0.006 0.169 0.159 1
 p 0.001 0.063 0.203 0.028 0.869 0.967 0.185 0.221  
B Protein HIF1α CAIX GAPDH GLUT1 LDH5 VEGFR2 HIF2α
HIF1α PC 1 -0.121 -0.023 -0.022 0.484** 0.420** 0.243**
 p . 0.156 0.793 0.797 0 0 0.01
CAIX PC -0.121 1 0.655** 0.653** 0.007 -0.127 -0.213*
 p 0.156 . 0 0 0.941 0.154 0.027
GAPDH PC -0.023 0.655** 1 0.699** -0.006 -0.08 -0.298**
 p 0.793 0 . 0 0.95 0.383 0.002
GLUT1 PC -0.022 0.653** 0.699** 1 -0.082 0 -0.301**
 p 0.797 0 0 . 0.368 0.998 0.002
LDH5 PC 0.484** 0.007 -0.006 -0.082 1 0.388** 0.138
 p 0 0.941 0.95 0.368 . 0 0.157
VEGFR2 PC 0.420** -0.127 -0.08 0 0.388** 1 0.109
 p 0 0.154 0.383 0.998 0 . 0.266
HIF2α PC 0.243** -0.213* -0.298** -0.301** 0.138 0.109 1
 p 0.01 0.027 0.002 0.002 0.157 0.266 .
** Correlation is significant at the 0.01 level (2-tailed).
* Correlation is significant at the 0.05 level (2-tailed).
p= Sig. (2 tailed).
PC= Correlation Coefficient.
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was associated with improved overall survival (p<0.001, 
HR=0.506) and VEGFR2 expression behaved similarly to 
HIF2α in this cohort: high expression (<median) predicted 
favorable prognosis (p<0.001, HR=0.436). In this cohort 
again, the combination of HIF1α and HIF2α expressions 
provided the best prognostic power: the HIF1α-high/
HIF2α-low patient group showed significantly poorer 
survival as compared with HIF1α-low/HIF2α-high 
patients (p<001, HR=3.27) (Table 5, Figure 4).
Analysis of HIF1α and HIF2α and HIF-
regulated genes in bone metastases compared 
with primary RCC
Neither HIF1α nor HIF2α mRNA expressions 
were found to be altered in bone metastases (Figure 1). 
However, HIF1α protein was shown to be significantly 
decreased (p/protein/=0.001) while HIF2α protein as 
determined by IHC was increased as compared with the 
primary site (p/protein/=0.023). None of the HIF-regulated 
genes or their protein products showed altered expressions 
in bone metastases (Figure 2), except for decreased 
VEGFR2 protein (p/protein/=0.006), and VEGF mRNA 
levels (p/mRNA/=0.020). The expressions of HIF1α and 
HIF2α and their regulated genes were also evaluated in 
relation to overall survival, as estimated from the time of 
operation of the bone metastasis. None of the investigated 
markers showed predictive power when split at median 
or mean values, either at mRNA or protein level (data not 
shown).
DISCUSSION
Despite the growing knowledge on the association 
between HIF1α and HIF2α dysfunction and ccRCC, 
limited literature is available on the role of HIF(s) 
as prognostic or predictive markers. In most studies, 
HIF1α was analyzed at the protein level using 
immunohistochemistry and nuclear overexpression was 
found to be associated with adverse prognosis [10, 16–
19]. Other studies identified cytoplasmic HIF1α or HIF2α 
[20] as a prognostic marker while in localized ccRCC, 
HIF1α did not prove to be part of the prognostic signature 
[10]. In a recent metaanalysis of 1258 RCC patients on 
the prognostic significance of HIF1α or HIF2α found high 
nuclear HIF1α expression was associated with poor overall 
survival, while high cytoplasmic expression of HIF2α 
was associated with poor cancer specific survival [19]. A 
previous study on 168 ccRCCs observed overexpression 
of HIF2α mRNA, which was associated with T stage and 
nuclear grade but not found to improve prognostication 
[21].
There is increasing controversy over the prognostic 
significance of HIF-regulated genes with the exception of 
CAIX, the protein expression of which is the most reliable 
marker of favorable prognosis [22, 23]. Several studies 
Figure 3: Prognostic potential for distant metastasis-free survival (DMFS) and overall survival (OS) related to 
expression of HIF1α (p
DMFS
= 0.435, HR
DMFS
 /±95%CI/ = 0.775 ± 0.639, pOS= 0.169, HROS /±95%CI/ = 0.497 ± 0.995), 
HIF2α (p
DMFS
= 0.001, HR
DMFS
/±95%CI/ = 0.035 ± 2.014, pOS= 0.019, HROS/±95%CI/ = 0.085 ± 2.068) and VEGFR2 
(p
DMFS
= 0.800, HR
DMFS
 /±95%CI/ = 1.085 ± 0.639, pOS= 0.609, HROS /±95%CI/ = 0.780 ± 0.952) at mRNA level split at 
the median values.
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Table 3: Univariate analysis of both protein (A) and mRNA (B) expressions for predicting prognosis of distant 
metastasis-free (DMFS) and overall survival (OS) 
A)
DMFS (protein) P HR 95% CI for HR
CAIX 0.047 1.895 1.01 3.558
GAPDH 0.002 2.735 1.44 5.194
GLUT1 0.013 2.259 1.19 4.286
HIF1α 0.005 1.481 1.428 1.537
HIF2α <0.001 0.083 0.026 0.272
LDH5 0.811 0.926 0.493 1.739
VEGFR2 0.994 1.002 0.521 1.929
OS (protein) P HR 95% CI for HR
CAIX 0.132 2.08 0.802 5.395
GAPDH 0.066 2.45 0.944 6.358
GLUT1 0.202 1.861 0.717 4.828
HIF1α 0.026 1.241 1.028 1.402
HIF2α 0.007 0.131 0.03 0.574
LDH5 0.753 0.858 0.331 2.225
VEGFR2 0.427 0.679 0.262 1.762
B)
DMFS P HR 95% CI for HR
CAIX 0.004 2.69 1.36 5.323
EPOR 0.001 0.286 0.139 0.59
GAPDH 0.582 0.838 0.446 1.573
GLUT1 0.015 0.438 0.224 0.853
HIF1α 0.023 2.03 1.401 2.618
HIF2α <0.001 0.109 0.042 0.28
LDH 0.219 0.67 0.354 1.269
VEGF 0.007 2.559 1.294 5.061
VEGFR <0.001 0.036 0.009 0.149
OS P HR 95% CI for HR
CAIX 0.548 1.156 0.72 1.858
EPOR 0.655 0.898 0.559 1.442
GAPDH 0.759 1.076 0.675 1.715
GLUT1 0.81 0.944 0.59 1.51
HIF1α 0.647 0.895 0.557 1.438
(Continued)
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Table 4: Multivariate analysis of the prognostic role of hypoxia inducible factor (HIF) protein expressions in 
primary metastatic and non-metastatic clear cell renal cell cancer (ccRCC) in two comparisons
 
 p HR 
95% CI for HR
Lower Upper
HIF2α 0.042 0.11 0.01 0.92
Gender 0.726 0.74 0.14 3.79
Fuhrman Grade 0.896 1.05 0.49 2.21
 p HR 95% CI for HR
   Lower Upper
HIF2α 0.036 0.10 0.01 0.86
HIF1α 0.164 0.35 0.08 1.52
Fuhrman Grade 0.965 1.01 0.49 2.09
HR: hazard ratio, 95%CI: 95% confidence interval. HIF1α and HIF2α: hypoxia inducible factor 1α and 2α.
OS P HR 95% CI for HR
HIF2α 0.434 0.823 0.505 1.341
LDH 0.762 1.075 0.673 1.716
VEGF 0.349 1.252 0.783 2.001
VEGFR 0.581 0.863 0.512 1.456
The groups were split at median expression level into “high and low” expressing clusters.
Figure 4: The prognostic performance of the identified HIF-index constructed from HIF1α and HIF2α: in our patient 
cohort for distant metastasis-free survival at protein level (left) and in the TCGA dataset for overall survival at mRNA 
level (right).
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found VEGF-A overexpression as adverse prognostic 
marker [17, 24, 25], while others opted for VEGFR1 [17]. 
In summary, data are either controversial or missing on 
various HIFs and on HIF-regulated gene expressions as 
prognostic markers in ccRCC, especially regarding bone 
metastatic diseases.
In the current study, we provided evidences that 
the prognostic roles of HIF1α and HIF2α are different 
in bone metastatic RCC: increased HIF1α and decreased 
HIF2α have adverse prognostic potential. However, only 
decreased HIF2α expression proved to be an independent 
prognostic marker. Since the validation cohort (TCGA) 
contained various visceral metastases and our results 
based on a bone metastatic cohort, we can assume that 
our results could be generalized to all metastatic RCCs. 
A novel finding of our study is that we provided evidence 
that protein and mRNA expressions of HIF1α are not 
altered in metastatic and non-metastatic primary ccRCC. 
However, its prognostic potential is clear, suggesting that 
beside VHL mutations other disturbances of the regulation 
of gene expressions - most probably mutations of 
transcription regulatory genes (PBRM1, ARID1A, BAP1, 
JARID2C, and SETD2) - affect their expression as well. 
[26] A further possible cause of the inverse dysregulation 
of HIF-1α and HIF-2α might be the defects of the genes 
(SETD2, JARID1C (lysine-specific demethylase 5C), 
UTX (ubiquitously transcribed tetratricopeptide repeat, 
X chromosome), etc.) of histone modification, which 
are known to be common in wild-type VHL RCC. They 
observed opposite functional roles for HIF-1α and HIF-
2α. HIF-1α regulated genes were associated with favorable 
prognosis while HIF-2α-regulated genes were associated 
with adverse prognosis. These data shows the existence of 
HIF-isoform-specific binding preferences of the regulated 
genes [27].
In accordance, our data confirmed the controversial 
roles of HIF-regulated genes as prognostic marker, since 
two out of seven HIF-regulated genes (CAIX, GLUT1) 
were found to be increased at mRNA and protein levels in 
bone metastatic primary ccRCC, and also had prognostic 
relevance, even though at protein and mRNA data seem 
contradictory, which needs further clarification. In an 
independent TCGA dataset of visceral metastatic RCCs, 
we have found that elevated VEGFR2 expression is a 
marker of favorable prognosis, which was confirmed in 
our bone metastatic cohort.
Bone metastasis of ccRCC is a frequent complication 
but relatively few studies have attempted to identify 
specific prognostic markers for this disease. Preliminary 
microarray data suggested HIF1α overexpression in 
parallel with its target genes VEGFR1, VEGFR2 to be 
involved [7]. Since we had access to bone metastases 
of ccRCCs, we ran this analysis on metastatic tissues as 
well, with the finding of decreased VEGFR2 and VEGF 
expressions. These data may suggest that bone metastases 
of ccRCCs may not be the best targets for antiangiogenic 
agents and provide a possible explanation for the relative 
therapy resistance.
Our study seems to be the first to clearly identify 
HIF2α as a significant marker of the (bone) metastatic 
potential of ccRCC. Several studies have recently 
found that HIF1α and HIF2α may be key regulators of 
the malignant phenotype of ccRCC with the finding 
of profound differences in their functions [26–28]. We 
also demonstrated that the combination of HIF1α and 
HIF2α expressions (either at mRNA or protein levels) 
Table 5: Multivariate analysis of the prognostic role of HIF-index at protein expression level in the currently utilized 
FFPE samples and the TCGA cohort
FFPE cohort p HR 
95% CI for HR
Lower Upper
HIF-index 0.022 3.576 1.203 10.624
Gender 0.280 0.534 0.171 1.667
Stage 0.379 1.319 0.711 2.448
Fuhrman Grade 0.435 0.773 0.405 1.476
TCGA cohort p HR   
HIF-index 0.048 2.05   
Age 0.016 1.03   
Gender 0.43 0.74   
Fuhrman Grade 0.032 1.72   
Stage <0.001 2.05   
HR: hazard ratio, 95%CI: 95% confidence interval. HIF-index: HIF1α and HIF2α index.
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Figure 5: Prognostic potential for OS related to expression of HIF1α (p=0.07), HIF2α (p=8.1E-04), VEGFR2 
(p=6.57E-05) at mRNA level based on Chip-seq data split at the median values.
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provides the best prognostic power in RCCs. Today 
the dichotomization of ccRCCs into favorable and 
adverse prognostic groups is achieved by using MSKCC 
nomogram or a newly developed gene signature [29]. The 
question still remains whether the angiogenic phenotype 
of ccRCC is linked to prognosis. Our data on VEGFR2 
expression linked to HIF2α rather than HIF1α expression 
suggest that the angiogenic phenotype of ccRCC may 
define the favorable prognosis subgroup, which can 
be more sensitive to antiangiogenic agents while the 
HIF1α-high/HIF2α-low subgroup may define the adverse 
prognosis subgroup of ccRCC, where VEGFR2 expression 
is also low. Whether this later subgroup can be linked to 
AKT (RAC-gamma serine/threonine-protein kinase) 
pathway alterations could well be the topic of further 
studies.
Conclusion
In our study, we identified HIF2α as an independent 
marker of the metastatic potential of ccRCC, however, 
unlike HIF1α, increased HIF2α expression is a favorable 
prognostic factor. The HIF-index is incorporating these 
two markers into a strong predictive biomarker validated 
in both cohorts.
MATERIALS AND METHODS
Patients and samples
We collected samples from 55 metastatic clear cell 
renal cell carcinoma (ccRCC) patients who have been 
operated at the Department of Orthopedics between 
1990-2008 for bone metastases. The primary tumors were 
gathered from pathological departments from all over the 
country for 40 cases (Table 1). Additionally, 59 ccRCC 
patients with no relapse on 102 months follow-up were 
selected from the archives of the Department of Urology 
and 2nd Department of Pathology as control group (Table 
1). Laboratory data for serum lactate dehydrogenase 
(LDH) was not available for all the patients, therefore the 
patients could not be classified according to the MSKCC 
criteria.
Our study is retrospective in design, and represents 
patients from the pre-antiangiogenic drug-era. The patients 
with metastatic tumors were postoperatively treated with 
clodronate 2x800mg per os/day and 9M IU interferon 
alpha (IFNα) subcutaneously and vinblastine according 
to the applying guidelines [12]. In that period, the 
targeted therapies were not available in our country. The 
institutional review board (IKEB #185/2007) approved the 
study. Signed informed consents of the patients are not 
needed since the retrospective design of the study and the 
anonym data management.
The investigated tissues were formalin-
fixed, paraffin-embedded (FFPE) material reviewed 
independently by three investigators (A.M.S., M.K., J.T.). 
TNM (Tumor Node Metastasis) classification was updated 
according to the 2009 TNM system and the grade was 
defined according to Fuhrman by a single renal pathologist 
(M.K.) [8]. After evaluation of cases for cellularity, 5 to 20 
pieces of 5 μm thick sections were cut from the blocks for 
nucleic acid isolation. In all cases where the tumor tissue 
was available after sectioning, 2 cores with 2 mm diameter 
were selected and punched for tissue microarray (TMA) 
construction (TMA Master, 3DHistech Ltd., Budapest, 
Hungary).
RNA purification and real-time polymerase 
chain reaction (qPCR)
RNA was extracted with QiagenRNeasy FFPE kit 
according to the manufacturer’s protocol. The amount of 
RNA was measured with ND-1000 Spectrophotometer 
(NanoDrop Products, Wilmington, DE, USA). High 
Capacity RNA-to-cDNA Master Mix from Applied 
Biosystems (ABI, Foster City, CA, USA) was used for 
transcription of 1000 ng RNA in 20 μl final volume for each 
case. The epMotion 5070 pipetting system (Eppendorf, 
Hamburg, Germany) was used to transfer ingredients of 
the PCR reaction to full-skirted white 384-well plates from 
Roche (Roche Diagnostics, Basel, Switzerland). The final 
volume was 20 μl, containing the sample (2 μl), water (7 
μl), TaqMan GeneExpression Master Mix (10 μl) and the 
adequate primers and hydrolysis probes (1 μl) for HIF2α; 
GAPDH, GLUT1; LDH5; EPOR; CAIX; VEGFR2; 
Beta-2-microglobulin (B2M); HIF1α; VEGF (all from 
ABI, Taqman Gene Expression Assay IDs, respectively: 
Hs01026142_m1; Hs02758991_g1; Hs00892681_m1; 
Hs00855332_g1; Hs00959432_g1; Hs00154208_m1; 
Hs00911705_g1; Hs02758991_g1; Hs00984230_m1; 
Hs00936371_m1; Hs00173626_ml). The reactions were 
running in a Lightcycler 480 real-time PCR system 
(Roche). The PCR program ran as follows: 10 min at 
95°C for enzyme activation and DNA denaturation, and 
40 PCR quantification cycles consisting of 95 °C for 15 s 
and 60 °C for 60 s. The raw data were exported in portable 
document format and converted to an Excel file (Microsoft 
Corp., Redmond, WA, USA). B2M (beta-2-microglobulin) 
was used as reference gene for the qPCR reactions [13].
Immunohistochemistry (IHC)
Reactions were performed on 4 μm thick sections 
after deparaffination and antigen retrieval for 30 minutes 
in Target Retrieval Solution (DAKO, Carpinteria, CA, 
USA). Visualization of HIF2α (NB100-132H, Novus 
Biologicals, Littleton, CO, USA), HIF1α, CAIX, GAPDH, 
GLUT1, LDH5 and VEGFR2 (ab85886, ab15086, ab9484, 
ab652, ab8365, ab9484 and ab39638, respectively, all 
from AbCam, Cambridge, UK) reactions was performed 
using Novolink Detection System (Leica Microsystems, 
Wetzlar, Germany) or Ventana Benchmark automated 
immunostainer (in case of CAIX and GLUT1). VEGF 
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and EPOR antibodies were not available in a validated 
manner on the market, thus, were not utilized. Slides were 
digitalized with Mirax MIDI scanner and evaluated with 
TMA modul software in MiraxViewer (v1.11, 3DHistech). 
Frequency of the reaction was scored on a 0-8 scale, 
intensity on a 0-3 scale measure. For further calculations, 
these two scores were summarized resulting in a 0-11 
combined score system.
Independent dataset for validation and 
computation
To assess the above genes’ expression in a 
separate patient cohort, we evaluated publicly available 
microarray profiles. For identifying relevant gene chips 
we searched the GEO (http://www.ncbi.nlm.nih.gov/
geo) and The Cancer Genome Atlas (TCGA) (http://
cancergenome.nih.gov/) repositories using the keywords 
“RCC”, “renal cell cancer” and “gpl96”, “gpl570” and 
“gpl571”. With these criteria, no datasets were published 
in the GEO or TCGA repository. We therefore used the 
RNA-Seq data for renal cancer patients published in 
the TCGA project (http://cancergenome.nih.gov/) and 
downloaded the pre-processed level 3 data generated 
using Illumina HiSeq 2000 RNA Sequencing Version 
2 platform. In these samples, gene expression levels 
were computed using a combination of MapSplice and 
RSEM (RNA-Seq by Expectation-Maximization). We 
combined individual patient files in R using the plyr 
package [14]. The following RNA-Seq probes (Symbol/
Illumina RNA-Seq ID) were used in the analysis: 
HIF1α/3091, HIF2α/2034, LDHA/3939, EPOR/2057 and 
VEGFR2/3791.
The complete published RCC database contained 
502 patients. The 86 patients who received neoadjuvant 
therapy (n=18), immunotherapy (n=28), tyrosine kinase 
inhibitor therapy (n=30) or chemotherapy (n=10) were 
excluded from the final analysis. Overall survival data 
was available for calculation for 399 patients. Follow-up 
period in case of the remaining patients was 36.6 ± 26.9 
months, with age 61.0 ± 12.4 months and 66% being male 
and 34% female.
Statistics
The qPCR and IHC data analysis was performed 
with SPSS 15.0 (SPSS Inc., Chicago, IL, USA). The 
“2^(ΔΔCq)” method and student’s T-test was applied 
for comparing relative expression results (qPCR values) 
between the investigated groups [15]. For non-parametric 
values (immunohistochemistry) Mann-Whitney U-test was 
used. Kaplan-Meier graphs were plotted to visualize the 
results using expression values as a cut-off determining 
high and low expression cohorts. Cox proportional hazard 
regression was performed in the tumor samples to compare 
the association between mRNA/protein expression and 
distant metastasis-free (DMFS) and overall survival (OS), 
using WinSTAT 2007 for Microsoft Excel (Robert K. 
Fitch Software, Germany) for datasets and SPSS 15.0 for 
clinical sample data. The ‘p’ values less than 0.05 were 
considered as being statistically significant.
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